Company BriaCell Therapeutics Corp.

Stocks

BCT

CA1079303071

Biotechnology & Medical Research

Market Closed - Toronto S.E. 23:59:57 28/10/2026 +04			5-day change	1st Jan Change
4.860 ^CAD	-2.99%		0.00%	-50.41%

10-23	Briacell Therapeutics Corp. Announces Clinical Biomarker Findings from Prospective Pooled Analysis of Patients with Metastatic Breast Cancer Treated with Immune Based Therapies Including the Briacell Regimen	CI
09-14	BriaCell Therapeutics Corp Receives Seventh Consecutive Positive DSMB Recommendation For Pivotal Phase 3 Bria-ABC Study Of Bria-IMT Plus Immune Checkpoint Inhibitor	CI

Business description: BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patientâ€™s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

Number of employees: 16

Sales by Activity: BriaCell Therapeutics Corp.

Fiscal Period: July	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)

See all business segments

Geographical breakdown of sales: BriaCell Therapeutics Corp.

Fiscal Period: July	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)

See all geographic segments

Executive Committee: BriaCell Therapeutics Corp.

Manager	Title	Age	Since
William Williams CEO	Chief Executive Officer	70	01/11/2016
Gadi Levin DFI	Director of Finance/CFO	54	01/02/2016
Guiseppe Del Priore CTO	Chief Tech/Sci/R&D Officer	65	16/02/2022
Miguel Lopez-Lago CTO	Chief Tech/Sci/R&D Officer	56	01/05/2021

See BRIACELL THERAPEUTICS CORP. governance

Composition of the Board of Directors: BriaCell Therapeutics Corp.

Director	Title	Age	Since
William Williams BRD	Director/Board Member	70	01/11/2016
Jamieson Bondarenko CHM	Chairman	41	24/04/2019
Rebecca Taub BRD	Director/Board Member	74	07/03/2019
Vaughn Embro-Pantalony BRD	Director/Board Member	68	18/03/2019
Martin Schmieg BRD	Director/Board Member	63	10/05/2016
Jane Gross BRD	Director/Board Member	69	18/01/2022

Composition of the Board of Directors

Shareholders: BriaCell Therapeutics Corp.

Name	Stocks	%	Valuation
Citadel Advisors LLC 8.238 %	716,699	8.238 %	3 M $
Cable Car Capital LP 2.492 %	216,821	2.492 %	927 994 $
Sabby Management LLC 0.9279 %	80,721	0.9279 %	345 486 $
Iridian Asset Management LLC 0.7471 %	65,000	0.7471 %	278 200 $
UBS Group AG (13f Subfiler) 0.5016 %	43,642	0.5016 %	186 788 $

Name	Stocks	%	Valuation
Citadel Advisors LLC (13f Subfiler) -	895,864	-	1 M $
Armistice Capital LLC -	536,600	-	622 456 $
Cable Car Capital LP -	321,898	-	373 402 $
Empery Asset Management LP -	300,000	-	348 000 $
MYDA Advisors LLC -	195,821	-	227 152 $

Name	Stocks	%	Valuation
Heights Capital Management, Inc. -	313,379	-	62 049 $
Sabby Management LLC -	120,802	-	23 919 $
G1 Execution Services LLC -	114,522	-	22 675 $
HRT Financial LP -	67,935	-	13 451 $
Two Sigma Securities LLC -	15,060	-	2 982 $

List of BRIACELL THERAPEUTICS CORP. shareholders

Company details: BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp.

Bellevue Centre

V7T 2X1, West Vancouver

+604 921 1810

http://www.briacell.com

address BriaCell Therapeutics Corp.(BCT)

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BRIACELL THERAPEUTICS CORP.	-2.99%	0.00%	-74.18%	-99.38%	31.03M
WUXI APPTEC CO., LTD.	+0.65%	-3.56%	+33.53%	+60.50%	63.48B
ARGENX SE	+1.76%	+2.10%	+12.10%	+81.21%	54.55B
LONZA GROUP AG	-0.94%	+0.77%	+8.85%	+100.19%	53.59B
IQVIA HOLDINGS INC.	+2.76%	+4.18%	+28.34%	+55.07%	44.75B
BEONE MEDICINES AG	+2.00%	-2.90%	+18.37%	+119.04%	41.62B
REVOLUTION MEDICINES, INC.	+1.34%	-3.98%	+225.44%	+914.08%	39.91B
CELLTRION, INC.	+0.64%	-3.85%	+11.71%	+45.57%	32.47B
GENMAB A/S	+29.06%	+48.65%	+106.84%	+92.73%	26.7B
WUXI BIOLOGICS (CAYMAN) INC.	+3.72%	-7.45%	+24.25%	-2.99%	23.36B
Average	+3.78%	-0.07%	+39.52%	+136.60%	38.05B
Weighted average by Cap.	+3.21%	-0.29%	+47.55%	+161.45%